布地耐德/福莫特罗和布地耐德治疗轻、中度持续性哮喘的药物经济学分析  

Clinical economic evaluation : treatment of Budesonide/Formoterol compared to Budesonide on mild-moderate persistant asthma

作　　者：何皓頔[1] 张铁锋[1] 修清玉[1] 

机构地区：[1]第二军医大学附属长征医院呼吸内科,上海200003

出　　处：《临床内科杂志》2008年第2期98-101,共4页Journal of Clinical Internal Medicine

摘　　要：目的采用随机、对照方法观察布地耐德/福莫特罗和布地耐德治疗的轻、中度持续性哮喘患者的临床药物经济学分析。方法收集40例轻、中度持续性哮喘患者,将其随机分为布地耐德/福莫特罗组(160μg/4.5μg,2吸/次,bid),单用布地耐德组(200μg,2吸/次,bid)各20例,随访12周后的成功治疗周、无症状日和未累及天数的平均成本-效果比以及增量效果比,并进行敏感度分析。结果经过治疗后,成功治疗周、无症状日和未累及天数的比例,布地耐德/福莫特罗组高于单用布地耐德组(P<0.05)。成功治疗周、无症状日和未累及天数的平均成果-效果比布地耐德/福莫特罗组高于单用布地耐德组(P<0.05),且受价格影响不大。结论布地耐德/福莫特罗在治疗轻、中度哮喘患者更经济有效。Objectives It was a randomized, open-minded, parallel-group study, evaluating the clinical economic evaluation of budesonide/formoterol and budesonide alone in patients with mild-to-moderate persistant asthma. Methods 40 mild-to-moderate persistant asthma to outpatients were were randomized into 12 weeks of twice-daily inhaled treatment with either budesonide/formoterol, 160μg/4. 5μg （ Symbicort Tu.rbuhaler, AstraZeneca, Lurid, Sweden）, or budesonide, 200μg （ Pulmicort Tu.rbuhaler, AstraZeneca, Lund, Sweden）and inhaled salbutamol as needed. The cost-effectiveness analysis and increment cost-effectiveness of succeesful-treatment weeks, symptom free days and uninvolved days were evaluated after 12 weeks treatment. And the sensitivity analysis was also done. Results After 12 weeks treatment,the average of succeesfultreatment weeks, symptom free days and uninvolved days in budesonide/formoterol group were better than that of in budesonide group （ P 〈 0.05）. The average cost-effectiveness of succeesful- treatment weeks, symptom free days and uninvolved days in budesonide/formoterol group were better than that of in budesonide group （P 〈 0.05） ,which was not affected by cost.

关 键 词：支气管哮喘 布地耐德/福莫特罗 布地耐德 临床经济学分析 成果-效果比 

分 类 号：R562.25[医药卫生—呼吸系统]